Miphic

Miphic is mitochondrial drug development and precision medicine platform. We develop a novel class of small molecule self-regulating mitochondrial function-targeting therapeutics with the help of the unique single-cell data generated with out platform technology.

TreatmentRevenue generatingUnited States

Request an introduction Visit website LinkedIn

See the full profile

The pitch deck, traction, financials and competitive detail are visible to approved investors, mentors and corporates. Log in or join EndCancer.Life to request access.

Company info

Countries of Operation: Norway
Founding Year: 2022
Number of Employees: 1–5

Company overview

Full Description: Miphic is the first mitochondrial drug development and precision medicine platform. We developed a first-in-class single-cell level platform technology that is based on quantification of changes in mitochondrial pH – a fundamental metabolic parameter responsible for energy production – and a growing number of additional non-mitochondrial parameters, in response to various treatments, e.g. nutrients, enzyme inhibitors, ionic load, drug candidates. This multiparametric functional readout is directly linked to metabolic processes driving consumption of oxygen and nutrients in mitochondria of living cells. The latest inflection point for the company is the launch of its own therapeutic pipeline in 2026. These multi-indication drugs target mitochondrial function in a self-regulating manner, protecting healthy cells and killing diseased cells at the same time. Miphic is already attracting clinical and corporate interest, having secured PoC clients and validation from leading cancer researchers in Scandinavia. We also entered into 3 corporate partnerships.
Areas of focus: Oncology / Mitochondria / Drug resistance / Precision medicine
Problem Statement: Miphic pioneers easy and reliable access to mitochondrial function screening for clinical patients, primarily focusing on blood cancers, where up to 60% of patients are non-responders to a very expensive therapy ($53K - $439K / patient). At the same time, in the last several years breakthrough in survival in blood cancer space came with the new drugs that target mitochondria and metabolism. When these drugs work - it's almost a miracle, but it happens in less than half of the cases, and nobody can predict when they would work. This is the unmet clinical need we are solving as a market entry point.

Interested in this innovator?

Send a short message. We’ll pass it to Miphic with your name and email, so they can reply.

Request an introduction

Create an account or log in to send this request. Already a member? Log in

Introductions to innovators are open to innovators, investors, mentors and corporates.

Miphic

Company info

Company overview

Interested in this innovator?

Product & IP

Team